{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T09:22:02Z","timestamp":1791537722650,"version":"4.3.4"},"reference-count":215,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Therapies"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.therap.2023.09.011","type":"journal-article","created":{"date-parts":[[2023,10,31]],"date-time":"2023-10-31T22:59:52Z","timestamp":1698793192000},"page":"239-270","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Cutaneous adverse drug reactions"],"prefix":"10.1016","volume":"79","author":[{"given":"Thomas","family":"Bettuzzi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Sanchez-Pena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B\u00e9n\u00e9dicte","family":"Lebrun-Vignes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.therap.2023.09.011_bib1000","doi-asserted-by":"crossref","first-page":"3358","DOI":"10.1001\/jama.1986.03380240052027","article-title":"Drug-induced cutaneous reactions: a report from the Boston collaborative drug surveillance program on 15 438 consecutive inpatients, 1975 to 1982","volume":"256","author":"Bigby","year":"1986","journal-title":"JAMA"},{"key":"10.1016\/j.therap.2023.09.011_bib1005","first-page":"765","article-title":"Rates of cutaneous reactions to drugs","volume":"137","author":"Bigby","year":"2001","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.therap.2023.09.011_bib1010","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1111\/j.1398-9995.1997.tb01017.x","article-title":"Comprehensive hospital drug monitoring (CHDM): adverse skin reactions, a 20-year survey","volume":"52","author":"Hunziker","year":"1997","journal-title":"Allergy"},{"key":"10.1016\/j.therap.2023.09.011_bib1015","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1111\/j.1365-2133.2003.05584.x","article-title":"A 6-month prospective survey of cutaneous drug reactions in a hospital setting","volume":"149","author":"Fiszenson-Albala","year":"2003","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.therap.2023.09.011_bib1020","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1111\/bcp.15510","article-title":"Incidence and preventability of hospital admissions for adverse drug reactions in France: A prospective observational study (IATROSTAT)","volume":"89","author":"Laroche","year":"2023","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.therap.2023.09.011_bib1025","first-page":"1266","article-title":"Survey on the activity of hospital departments of dermatology in France","volume":"129","author":"Modeste","year":"2002","journal-title":"Ann Dermatol Venereol"},{"key":"10.1016\/j.therap.2023.09.011_bib1030","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/S0151-9638(06)70987-5","article-title":"Activit\u00e9 de consultation de trois services de dermatologie hospitalo-universitaires fran\u00e7ais","volume":"133","author":"Lambert","year":"2006","journal-title":"Ann Dermatol Venereol"},{"key":"10.1016\/j.therap.2023.09.011_bib1035","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/S0895-4356(98)00041-9","article-title":"Skin reactions to antibacterial agents in general practice","volume":"51","author":"van der Linden","year":"1998","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.therap.2023.09.011_bib1040","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1001\/archderm.136.7.849","article-title":"Antibiotic rashes in children: a survey in a private practice setting","volume":"136","author":"Ibia","year":"2000","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.therap.2023.09.011_bib1045","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.anai.2017.07.009","article-title":"Frequency of self-reported drug allergy","volume":"119","author":"Sousa-Pinto","year":"2017","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.therap.2023.09.011_bib1050","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.iac.2022.01.004","article-title":"The use of electronic health records to study drug-induced hypersensitivity reactions from 2000 to 2021","volume":"42","author":"Bassir","year":"2022","journal-title":"Immunol Allergy Clin North Am"},{"key":"10.1016\/j.therap.2023.09.011_bib1055","doi-asserted-by":"crossref","first-page":"96","DOI":"10.5414\/ALX01508E","article-title":"Epidemiology of cutaneous adverse drug reactions","volume":"1","author":"Mockenhaupt","year":"2017","journal-title":"Allergol Sel"},{"key":"10.1016\/j.therap.2023.09.011_bib1060","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1111\/all.15612","article-title":"Different phenotypes of drug-induced anaphylaxis\u2013Data from the European Anaphylaxis Registry","volume":"78","author":"Hanschmann","year":"2023","journal-title":"Allergy"},{"key":"10.1016\/j.therap.2023.09.011_bib1065","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.clindermatol.2004.06.012","article-title":"Life-threatening acute adverse cutaneous drug reactions","volume":"23","author":"Wolf","year":"2005","journal-title":"Clin Dermatol"},{"key":"10.1016\/j.therap.2023.09.011_bib1070","doi-asserted-by":"crossref","first-page":"e1424","DOI":"10.1542\/peds.2012-1575","article-title":"Incidence of rash after amoxicillin treatment in children with infectious mononucleosis","volume":"131","author":"Chovel-Sella","year":"2013","journal-title":"Pediatrics"},{"key":"10.1016\/j.therap.2023.09.011_bib1075","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1097\/00002030-199403000-00006","article-title":"Acetylation phenotype and cutaneous hypersensitivity to trimethoprim-sulphamethoxazole in HIV-infected patients","volume":"8","author":"Carr","year":"1994","journal-title":"AIDS"},{"key":"10.1016\/j.therap.2023.09.011_bib1080","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/j.annder.2015.07.010","article-title":"\u00c9ryth\u00e8me pigment\u00e9 fixe\u00a0: \u00e9pid\u00e9miologie, physiopathologie, clinique, diagnostic diff\u00e9rentiel et modalit\u00e9s de prise en charge","volume":"142","author":"Valeyrie-Allanore","year":"2015","journal-title":"Ann Dermatol Venereol"},{"key":"10.1016\/j.therap.2023.09.011_bib1085","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/S0190-9622(94)70007-9","article-title":"Genetic susceptibility to fixed drug eruption: Evidence for a link with HLA-B22","volume":"30","author":"Pellicano","year":"1994","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.therap.2023.09.011_bib1090","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1067\/mjd.2001.117854","article-title":"Fixed drug eruption induced by trimethoprim-sulfamethoxazole: Evidence for a link to HLA-A30 B13 Cw6 haplotype","volume":"45","author":"\u00d6zkaya-Bayazit","year":"2001","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.therap.2023.09.011_bib1095","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1684\/ejd.2010.0980","article-title":"A three-year-analysis of fixed drug eruptions in hospital settings in France","volume":"20","author":"Brahimi","year":"2010","journal-title":"Eur J Dermatol"},{"key":"10.1016\/j.therap.2023.09.011_bib1100","first-page":"288","article-title":"Drug related clinical pattern in fixed drug eruption","volume":"10","author":"Ozkaya-Bayazit","year":"2000","journal-title":"Eur J Dermatol EJD"},{"key":"10.1016\/j.therap.2023.09.011_bib1105","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1111\/bjd.12133","article-title":"Prognosis of generalized bullous fixed drug eruption: comparison with Stevens-Johnson syndrome and toxic epidermal necrolysis: Prognosis of GBFDE vs SJS\/TEN","volume":"168","author":"Lipowicz","year":"2013","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.therap.2023.09.011_bib1110","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1684\/ejd.2021.4051","article-title":"Clinical and histological features of fixed drug eruption: a single-centre series of 73 cases with comparison between bullous and non-bullous forms","volume":"31","author":"Perron","year":"2021","journal-title":"Eur J Dermatol"},{"key":"10.1016\/j.therap.2023.09.011_bib1115","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/S0190-9622(87)70220-5","article-title":"Nonpigmenting fixed drug eruption as a distinctive reaction pattern: Examples caused by sensitivity to pseudoephedrine hydrochloride and tetrahydrozoline","volume":"17","author":"Shelley","year":"1987","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.therap.2023.09.011_bib1120","first-page":"201","article-title":"Fixed drug eruption: a disease mediated by self-inflicted responses of intraepidermal T cells","volume":"17","author":"Shiohara","year":"2007","journal-title":"Eur J Dermatol"},{"key":"10.1016\/j.therap.2023.09.011_bib1125","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1111\/j.1365-2133.2008.08516.x","article-title":"In vivo dynamics of intraepidermal CD8+ T cells and CD4+ T cells during the evolution of fixed drug eruption","volume":"158","author":"Mizukawa","year":"2008","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.therap.2023.09.011_bib1130","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1046\/j.1365-2133.2001.04422.x","article-title":"Current causes of fixed drug eruption in the UK","volume":"145","author":"Savin","year":"2001","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.therap.2023.09.011_bib1135","first-page":"1289","article-title":"Fixed drug eruptions \u2013 the common and novel culprits since 2000","volume":"20","author":"McClatchy","year":"2022","journal-title":"J Dtsch Dermatol Ges"},{"key":"10.1016\/j.therap.2023.09.011_bib1140","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1684\/ejd.2013.2055","article-title":"\u201cCutaneous adverse drug reactions\u201d are not always drug-induced","volume":"23","author":"Raison-Peyron","year":"2013","journal-title":"Eur J Dermatol"},{"key":"10.1016\/j.therap.2023.09.011_bib1145","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1111\/j.0105-1873.2004.00445.x","article-title":"Baboon syndrome resulting from systemic drugs: is there strife between SDRIFE and allergic contact dermatitis syndrome?","volume":"51","author":"Hausermann","year":"2004","journal-title":"Contact Dermatitis"},{"key":"10.1016\/j.therap.2023.09.011_bib1150","doi-asserted-by":"crossref","first-page":"3","DOI":"10.5070\/D32WS5H2S0","article-title":"Systemic drug-related intertriginous and flexural exanthema (SDRIFE)","volume":"15","author":"Elmariah","year":"2009","journal-title":"Dermatol Online J"},{"key":"10.1016\/j.therap.2023.09.011_bib1155","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1111\/all.12168","article-title":"Severe drug-induced anaphylaxis: analysis of 333 cases recorded by the Allergy Vigilance Network from 2002 to 2010","volume":"68","author":"Renaudin","year":"2013","journal-title":"Allergy"},{"key":"10.1016\/j.therap.2023.09.011_bib1160","first-page":"321","article-title":"Immediate hypersensitivity is rarely implicated in drug induced urticaria","volume":"130","author":"Cousin","year":"2003","journal-title":"Ann Dermatol Venereol"},{"key":"10.1016\/j.therap.2023.09.011_bib1165","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1161\/HYPERTENSIONAHA.108.110270","article-title":"Angioedema incidence in US veterans initiating angiotensin-converting enzyme inhibitors","volume":"51","author":"Miller","year":"2008","journal-title":"Hypertension"},{"key":"10.1016\/j.therap.2023.09.011_bib1170","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.revmed.2012.12.017","article-title":"Prise en charge des angi\u0153d\u00e8mes induits par les inhibiteurs de l\u2019enzyme de conversion de l\u2019angiotensine\u00a0: recommandations du Centre de r\u00e9f\u00e9rence national des angi\u0153d\u00e8mes","volume":"34","author":"Nosbaum","year":"2013","journal-title":"Rev Med Interne"},{"key":"10.1016\/j.therap.2023.09.011_bib1175","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1001\/jamadermatol.2021.5390","article-title":"Clinical characteristics, disease course, and outcomes of patients with acute generalized exanthematous pustulosis in the US","volume":"158","author":"Creadore","year":"2022","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.therap.2023.09.011_bib1180","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1111\/bjd.12502","article-title":"Systemic involvement of acute generalized exanthematous pustulosis: a retrospective study on 58 patients","volume":"169","author":"Hotz","year":"2013","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.therap.2023.09.011_bib1185","doi-asserted-by":"crossref","first-page":"397","DOI":"10.3390\/jcm11020397","article-title":"Drug triggers and clinic of acute generalized exanthematous pustulosis (AGEP): a literature case series of 297 patients","volume":"11","author":"Vallejo-Yag\u00fce","year":"2022","journal-title":"J Clin Med"},{"key":"10.1016\/j.therap.2023.09.011_bib1190","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1034\/j.1600-0560.2001.028003113.x","article-title":"Acute generalized exanthematous pustulosis (AGEP) - A clinical reaction pattern: Acute generalized exanthematous pustulosis","volume":"28","author":"Sidoroff","year":"2001","journal-title":"J Cutan Pathol"},{"key":"10.1016\/j.therap.2023.09.011_bib1195","doi-asserted-by":"crossref","first-page":"363","DOI":"10.2340\/00015555-0438","article-title":"Clinical manifestations and characteristics of patients with acute generalized exanthematous pustulosis in Asia","volume":"88","author":"Chang","year":"2008","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.therap.2023.09.011_bib1200","doi-asserted-by":"crossref","first-page":"e776","DOI":"10.1111\/jdv.18940","article-title":"Acute generalized exanthematous pustulosis: Clinico-biological profile and inducing drugs in 83 patients","volume":"37","author":"Weiss","year":"2023","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.therap.2023.09.011_bib1205","doi-asserted-by":"crossref","first-page":"1996","DOI":"10.1016\/S0140-6736(16)30378-6","article-title":"Severe cutaneous adverse reactions to drugs","volume":"390","author":"Duong","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.therap.2023.09.011_bib1210","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1001\/archderm.1991.01680080069004","article-title":"Acute generalized exanthematous pustulosis: analysis of 63 cases","volume":"127","author":"Roujeau","year":"1991","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.therap.2023.09.011_bib1215","doi-asserted-by":"crossref","first-page":"3041","DOI":"10.1016\/j.jaip.2021.02.060","article-title":"DRESS and AGEP reactions to iodinated contrast media: a french case series","volume":"9","author":"Soria","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.therap.2023.09.011_bib1220","doi-asserted-by":"crossref","first-page":"4486","DOI":"10.3390\/jcm10194486","article-title":"A network analysis of drug combinations associated with acute generalized exanthematous pustulosis (AGEP)","volume":"10","author":"Martinez-De La Torre","year":"2021","journal-title":"J Clin Med"},{"key":"10.1016\/j.therap.2023.09.011_bib1225","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1111\/j.1365-2133.2007.08156.x","article-title":"Risk factors for acute generalized exanthematous pustulosis (AGEP)\u2014results of a multinational case\u2013control study (EuroSCAR)","volume":"157","author":"Sidoroff","year":"2007","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.therap.2023.09.011_bib1230","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.jaci.2022.12.005","article-title":"Updates on the immunopathology and genomics of severe cutaneous adverse drug reactions","volume":"151","author":"Gibson","year":"2023","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.therap.2023.09.011_bib1235","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1056\/NEJMoa1013068","article-title":"Interleukin-36\u2013receptor antagonist deficiency and generalized pustular psoriasis","volume":"365","author":"Marrakchi","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.therap.2023.09.011_bib1240","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1038\/jid.2013.44","article-title":"Rare variations in IL36RN in severe adverse drug reactions manifesting as acute generalized exanthematous pustulosis","volume":"133","author":"Navarini","year":"2013","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.therap.2023.09.011_bib1245","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1001\/jamadermatol.2014.3848","article-title":"Homozygous missense mutation in IL36RN in generalized pustular dermatosis with intraoral involvement compatible with both AGEP and generalized pustular psoriasis","volume":"151","author":"Navarini","year":"2015","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.therap.2023.09.011_bib1250","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1016\/S0002-9440(10)64486-0","article-title":"Acute generalized exanthematous pustulosis","volume":"161","author":"Schmid","year":"2002","journal-title":"Am J Pathol"},{"key":"10.1016\/j.therap.2023.09.011_bib1255","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1016\/j.jid.2018.10.023","article-title":"Culprit drugs induce specific IL-36 overexpression in acute generalized exanthematous pustulosis","volume":"139","author":"Meier-Schiesser","year":"2019","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.therap.2023.09.011_bib1260","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1111\/j.1468-3083.2010.03771.x","article-title":"Increased circulating Th17 frequencies and serum IL-22 levels in patients with acute generalized exanthematous pustulosis: Th17 and IL-22 in AGEP","volume":"25","author":"Kabashima","year":"2011","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.therap.2023.09.011_bib1265","doi-asserted-by":"crossref","first-page":"129","DOI":"10.2332\/allergolint.13-LE-0582","article-title":"Hapten-specific Th17 cells in the peripheral blood of \u03b2-lactam-induced AGEP","volume":"63","author":"Fil\u00ec","year":"2014","journal-title":"Allergol Int"},{"key":"10.1016\/j.therap.2023.09.011_bib1270","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1172\/JCI12118","article-title":"T-cell involvement in drug-induced acute generalized exanthematous pustulosis","volume":"107","author":"Britschgi","year":"2001","journal-title":"J Clin Invest"},{"key":"10.1016\/j.therap.2023.09.011_bib1275","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1007\/s00403-014-1488-0","article-title":"Innate immune cells express IL-17A\/F in acute generalized exanthematous pustulosis and generalized pustular psoriasis","volume":"306","author":"Kakeda","year":"2014","journal-title":"Arch Dermatol Res"},{"key":"10.1016\/j.therap.2023.09.011_bib1280","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1111\/j.1468-3083.2006.02026.x","article-title":"Overlap of acute generalized exanthematous pustulosis and toxic epidermal necrolysis: response to antitumour necrosis factor-alpha antibody infliximab: report of three cases","volume":"21","author":"Meiss","year":"2007","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.therap.2023.09.011_bib1285","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.jaad.2020.02.069","article-title":"Cyclosporine for treatment of acute generalized exanthematous pustulosis: A retrospective analysis","volume":"83","author":"Yanes","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.therap.2023.09.011_bib1290","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1001\/archderm.1990.01670250043005","article-title":"Toxic epidermal necrolysis (Lyell syndrome): incidence and drug etiology in France, 1981-1985","volume":"126","author":"Roujeau","year":"1990","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.therap.2023.09.011_bib1295","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1111\/bjd.18424","article-title":"Incidence of and mortality from epidermal necrolysis (Stevens\u2013Johnson syndrome\/toxic epidermal necrolysis) in France during 2003-16: a four-source capture\u2013recapture estimate","volume":"182","author":"Chaby","year":"2020","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.therap.2023.09.011_bib1300","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1016\/j.jid.2017.01.031","article-title":"The epidemiology of Stevens-Johnson syndrome and toxic epidermal necrolysis in the UK","volume":"137","author":"Frey","year":"2017","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.therap.2023.09.011_bib1305","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1001\/archderm.1987.01660330077013","article-title":"The culprit drugs in 87 cases of toxic epidermal necrolysis (Lyell's Syndrome)","volume":"123","author":"Guillaume","year":"1987","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.therap.2023.09.011_bib1310","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1007\/s001340050492","article-title":"Pulmonary complications in toxic epidermal necrolysis: a prospective clinical study","volume":"23","author":"Lebargy","year":"1997","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.therap.2023.09.011_bib1315","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1111\/bjd.17428","article-title":"Gastrointestinal involvement in Stevens\u2013Johnson syndrome and toxic epidermal necrolysis: a retrospective case series","volume":"180","author":"Gendreau","year":"2019","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.therap.2023.09.011_bib1320","doi-asserted-by":"crossref","first-page":"e29","DOI":"10.1016\/j.jaad.2011.10.007","article-title":"Prognostic value of histologic features of toxic epidermal necrolysis","volume":"68","author":"Valeyrie-Allanore","year":"2013","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.therap.2023.09.011_bib1325","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1097\/MD.0b013e3181ca4290","article-title":"Bacteremia in Stevens-Johnson syndrome and toxic epidermal necrolysis: epidemiology, risk factors, and predictive value of skin cultures","volume":"89","author":"de Prost","year":"2010","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.therap.2023.09.011_bib1330","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1056\/NEJM199512143332404","article-title":"Medication use and the risk of Stevens\u2013Johnson syndrome or toxic epidermal necrolysis","volume":"333","author":"Roujeau","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1016\/j.therap.2023.09.011_bib1335","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/sj.jid.5701033","article-title":"Stevens\u2013Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-Study","volume":"128","author":"Mockenhaupt","year":"2008","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.therap.2023.09.011_bib1340","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1038\/clpt.2009.252","article-title":"ALDEN, an algorithm for assessment of drug causality in Stevens\u2013Johnson syndrome and toxic epidermal necrolysis: comparison with case\u2013control analysis","volume":"88","author":"Sassolas","year":"2010","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.therap.2023.09.011_bib1345","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1016\/j.jaad.2020.10.091","article-title":"Changing spectrum of suspected drugs of epidermal necrolysis: an WHO pharmacovigilance database analysis from 1997 to 2020","volume":"85","author":"Bettuzzi","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.therap.2023.09.011_bib1350","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1097\/CMR.0000000000000819","article-title":"Severe blistering eruptions induced by immune checkpoint inhibitors: a multicentre international study of 32 cases","volume":"32","author":"Ingen-Housz-Oro","year":"2022","journal-title":"Melanoma Res"},{"key":"10.1016\/j.therap.2023.09.011_bib1355","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1016\/j.jid.2016.03.023","article-title":"Morbidity and mortality of Stevens-Johnson syndrome and toxic epidermal necrolysis in United States adults","volume":"136","author":"Hsu","year":"2016","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.therap.2023.09.011_bib1360","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1093\/bjd\/ljad226","article-title":"Comparison of idiopathic and drug-induced epidermal necrolysis in children","volume":"189","author":"Welfringer-Morin","year":"2023","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.therap.2023.09.011_bib1365","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1038\/428486a","article-title":"A marker for Stevens\u2013Johnson syndrome","volume":"428","author":"Chung","year":"2004","journal-title":"Nature"},{"key":"10.1016\/j.therap.2023.09.011_bib1370","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1056\/NEJMoa1013297","article-title":"HLA-A*3101 and carbamazepine-induced hypersensitivity reactions in Europeans","volume":"364","author":"McCormack","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.therap.2023.09.011_bib1375","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1038\/tpj.2013.40","article-title":"HLA-A*31:01 and different types of carbamazepine-induced severe cutaneous adverse reactions: an international study and meta-analysis","volume":"14","author":"Genin","year":"2014","journal-title":"Pharmacogenomics J"},{"key":"10.1016\/j.therap.2023.09.011_bib1380","doi-asserted-by":"crossref","first-page":"4134","DOI":"10.1073\/pnas.0409500102","article-title":"HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol","volume":"102","author":"Hung","year":"2005","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/j.therap.2023.09.011_bib1385","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1111\/bjd.12389","article-title":"HLA-B*58:01 is a risk factor for allopurinol-induced DRESS and Stevens-Johnson syndrome\/toxic epidermal necrolysis in a Portuguese population","volume":"169","author":"Gon\u00e7alo","year":"2013","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.therap.2023.09.011_bib1390","doi-asserted-by":"crossref","first-page":"8071","DOI":"10.4049\/jimmunol.0804002","article-title":"Defective regulatory T cells in patients with severe drug eruptions: timing of the dysfunction is associated with the pathological phenotype and outcome","volume":"182","author":"Takahashi","year":"2009","journal-title":"J Immunol"},{"key":"10.1016\/j.therap.2023.09.011_bib1395","doi-asserted-by":"crossref","first-page":"eabe0013","DOI":"10.1126\/sciadv.abe0013","article-title":"Massive clonal expansion of polycytotoxic skin and blood CD8 + T cells in patients with toxic epidermal necrolysis","volume":"7","author":"Villani","year":"2021","journal-title":"Sci Adv"},{"key":"10.1016\/j.therap.2023.09.011_bib1400","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1038\/nm.1884","article-title":"Granulysin is a key mediator for disseminated keratinocyte death in Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"14","author":"Chung","year":"2008","journal-title":"Nat Med"},{"key":"10.1016\/j.therap.2023.09.011_bib1405","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1007\/BF00406477","article-title":"Lymphopenia and abnormal balance of T-lymphocyte subpopulations in toxic epidermal necrolysis","volume":"277","author":"Roujeau","year":"1984","journal-title":"Arch Dermatol Res"},{"key":"10.1016\/j.therap.2023.09.011_bib1410","doi-asserted-by":"crossref","first-page":"245ra95","DOI":"10.1126\/scitranslmed.3008227","article-title":"An annexin A1\u2013FPR1 interaction contributes to necroptosis of keratinocytes in severe cutaneous adverse drug reactions","volume":"6","author":"Saito","year":"2014","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.therap.2023.09.011_bib1415","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1016\/j.jid.2016.11.034","article-title":"Interleukin-15 is associated with severity and mortality in Stevens-Johnson syndrome\/toxic epidermal necrolysis","volume":"137","author":"Su","year":"2017","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.therap.2023.09.011_bib1420","doi-asserted-by":"crossref","first-page":"eaaw6142","DOI":"10.1126\/scitranslmed.aaw6142","article-title":"Plasma exosomal miR-375-3p regulates mitochondria-dependent keratinocyte apoptosis by targeting XIAP in severe drug-induced skin reactions","volume":"12","author":"Zhang","year":"2020","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.therap.2023.09.011_bib1425","doi-asserted-by":"crossref","first-page":"eaax2398","DOI":"10.1126\/scitranslmed.aax2398","article-title":"Neutrophils initiate and exacerbate Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"13","author":"Kinoshita","year":"2021","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.therap.2023.09.011_bib1430","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.jaip.2018.05.037","article-title":"Differential expression of alarmins: IL-33 as a candidate marker for early diagnosis of toxic epidermal necrolysis","volume":"7","author":"Adachi","year":"2019","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.therap.2023.09.011_bib1435","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.1038\/jid.2015.90","article-title":"Upregulated RIP3 expression potentiates MLKL phosphorylation\u2013mediated programmed necrosis in toxic epidermal necrolysis","volume":"135","author":"Kim","year":"2015","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.therap.2023.09.011_bib1440","first-page":"247","article-title":"Trends in mortality rates for Stevens\u2013Johnson syndrome and toxic epidermal necrolysis: experience of a single centre in France between 1997 and 2017","volume":"182","author":"Bettuzzi","year":"2020","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.therap.2023.09.011_bib1445","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1046\/j.1523-1747.2000.00061.x","article-title":"SCORTEN: a severity-of-illness score for toxic epidermal necrolysis","volume":"115","author":"Fouchard","year":"2000","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.therap.2023.09.011_bib1450","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/j.jaad.2021.04.082","article-title":"Performance of ABCD-10 and SCORTEN mortality prediction models in a cohort of patients with Stevens-Johnson syndrome\/toxic epidermal necrolysis","volume":"85","author":"Duplisea","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.therap.2023.09.011_bib1455","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1001\/jamadermatol.2020.3654","article-title":"Assessment and comparison of performance of ABCD-10 and SCORTEN in prognostication of epidermal necrolysis","volume":"156","author":"Koh","year":"2020","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.therap.2023.09.011_bib1460","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1001\/jamadermatol.2021.5119","article-title":"Improvement of mortality prognostication in patients with epidermal necrolysis: the role of novel inflammatory markers and proposed revision of SCORTEN (Re-SCORTEN)","volume":"158","author":"Koh","year":"2022","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.therap.2023.09.011_bib1465","doi-asserted-by":"crossref","first-page":"e514","DOI":"10.1111\/jdv.18734","article-title":"Comparison of performance of SCORTEN, ABCD-10 and Re-SCORTEN in a cohort of patients with Stevens\u2013Johnson syndrome\/toxic epidermal necrolysis","volume":"37","author":"Hsieh","year":"2023","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.therap.2023.09.011_bib1470","doi-asserted-by":"crossref","first-page":"e382","DOI":"10.1111\/jdv.18578","article-title":"Novel inflammatory markers and in-hospital mortality in epidermal necrolysis\u2014A monocentric study of 137 patients","volume":"37","author":"Bettuzzi","year":"2023","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.therap.2023.09.011_bib1475","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1111\/bjd.19893","article-title":"Supportive care in the acute phase of Stevens\u2013Johnson syndrome and toxic epidermal necrolysis: an international, multidisciplinary Delphi-based consensus","volume":"185","author":"Br\u00fcggen","year":"2021","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.therap.2023.09.011_bib1480","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1001\/archderm.136.3.323","article-title":"Toxic epidermal necrolysis and Stevens-Johnson syndrome: does early withdrawal of causative drugs decrease the risk of death?","volume":"136","author":"Garcia-Doval","year":"2000","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.therap.2023.09.011_bib1485","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1001\/jamadermatol.2021.3154","article-title":"Assessment of treatment approaches and outcomes in Stevens-Johnson syndrome and toxic epidermal necrolysis: insights from a Pan-European multicenter study","volume":"157","author":"Kridin","year":"2021","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.therap.2023.09.011_bib1490","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/s41586-023-06217-y","article-title":"PD-1 maintains CD8 T cell tolerance towards cutaneous neoantigens","volume":"619","author":"Damo","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.therap.2023.09.011_bib1495","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1172\/JCI93349","article-title":"Randomized, controlled trial of TNF-\u03b1 antagonist in CTL-mediated severe cutaneous adverse reactions","volume":"128","author":"Wang","year":"2018","journal-title":"J Clin Invest"},{"key":"10.1016\/j.therap.2023.09.011_bib1500","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/j.jid.2017.12.034","article-title":"Cyclosporine for epidermal necrolysis: absence of beneficial effect in a retrospective cohort of 174 patients\u2014exposed\/unexposed and propensity score-matched analyses","volume":"138","author":"Poizeau","year":"2018","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.therap.2023.09.011_bib1505","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.cytogfr.2016.06.001","article-title":"Interleukin 15: A key cytokine for immunotherapy","volume":"31","author":"Patidar","year":"2016","journal-title":"Cytokine Growth Factor Rev"},{"key":"10.1016\/j.therap.2023.09.011_bib1510","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1056\/NEJMoa1917635","article-title":"Ruxolitinib for glucocorticoid-refractory acute graft-versus-host disease","volume":"382","author":"Zeiser","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.therap.2023.09.011_bib1515","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1002\/ajh.20570","article-title":"Analysis of serum granulysin in patients with hematopoietic stem-cell transplantation: Its usefulness as a marker of graft-versus-host reaction","volume":"81","author":"Nagasawa","year":"2006","journal-title":"Am J Hematol"},{"key":"10.1016\/j.therap.2023.09.011_bib1520","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1111\/jdv.18808","article-title":"Management and treatment outcome of DRESS patients in Europe: An international multicentre retrospective study of 141 cases","volume":"37","author":"Kridin","year":"2023","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.therap.2023.09.011_bib1525","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1111\/bjd.12501","article-title":"Drug reaction with eosinophilia and systemic symptoms (DRESS): an original multisystem adverse drug reaction. Results from the prospective RegiSCAR study","volume":"169","author":"Kardaun","year":"2013","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.therap.2023.09.011_bib1530","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1111\/j.1365-2133.2006.07704.x","article-title":"Variability in the clinical pattern of cutaneous side-effects of drugs with systemic symptoms: does a DRESS syndrome really exist?","volume":"156","author":"Kardaun","year":"2007","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.therap.2023.09.011_bib1535","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2017-221401","article-title":"Acute interstitial nephritis and DRESS syndrome without eosinophilia associated with cefepime","author":"Qadri","year":"2017","journal-title":"BMJ Case Rep"},{"key":"10.1016\/j.therap.2023.09.011_bib1540","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1710-1492-7-16","article-title":"DRESS with delayed onset acute interstitial nephritis and profound refractory eosinophilia secondary to Vancomycin","volume":"7","author":"O\u2019Meara","year":"2011","journal-title":"Allergy Asthma Clin Immunol"},{"key":"10.1016\/j.therap.2023.09.011_bib1545","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1001\/archderm.145.1.67","article-title":"Twelve-year analysis of severe cases of drug reaction with eosinophilia and systemic symptoms: a cause of unpredictable multiorgan failure","volume":"145","author":"Eshki","year":"2009","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.therap.2023.09.011_bib1550","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1056\/NEJM199411103311906","article-title":"Severe adverse cutaneous reactions to drugs","volume":"331","author":"Roujeau","year":"1994","journal-title":"N Engl J Med"},{"key":"10.1016\/j.therap.2023.09.011_bib1555","doi-asserted-by":"crossref","first-page":"46ra62","DOI":"10.1126\/scitranslmed.3001116","article-title":"Drug reaction with eosinophilia and systemic symptoms (DRESS): a multiorgan antiviral T cell response","volume":"2","author":"Picard","year":"2010","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.therap.2023.09.011_bib1560","first-page":"301","article-title":"Association of human herpesvirus 6 infection with drug reaction with eosinophilia and systemic symptoms","volume":"137","author":"Descamps","year":"2001","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.therap.2023.09.011_bib1565","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1111\/j.1365-2133.2006.07238.x","article-title":"Several herpesviruses can reactivate in a severe drug-induced multiorgan reaction in the same sequential order as in graft-versus-host disease: Herpesvirus reactivation in drug reaction","volume":"155","author":"Kano","year":"2006","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.therap.2023.09.011_bib1570","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1111\/all.12138","article-title":"Skin recruitment of monomyeloid precursors involves human herpesvirus-6 reactivation in drug allergy","volume":"68","author":"Hashizume","year":"2013","journal-title":"Allergy"},{"key":"10.1016\/j.therap.2023.09.011_bib1575","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1038\/s41591-019-0733-7","article-title":"Targeted therapy guided by single-cell transcriptomic analysis in drug-induced hypersensitivity syndrome: a case report","volume":"26","author":"Kim","year":"2020","journal-title":"Nat Med"},{"key":"10.1016\/j.therap.2023.09.011_bib1580","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1111\/bjd.13683","article-title":"Histopathology of drug rash with eosinophilia and systemic symptoms syndrome: a morphological and phenotypical study","volume":"173","author":"Ortonne","year":"2015","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.therap.2023.09.011_bib1585","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/j.jaad.2019.09.036","article-title":"Drug reaction with eosinophilia and systemic symptoms may occur within 2 weeks of drug exposure: A retrospective study","volume":"82","author":"Soria","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.therap.2023.09.011_bib1590","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/j.amjmed.2011.01.017","article-title":"The DRESS syndrome: a literature review","volume":"124","author":"Cacoub","year":"2011","journal-title":"Am J Med"},{"key":"10.1016\/j.therap.2023.09.011_bib1595","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1016\/j.jaci.2020.08.003","article-title":"Whole genome sequencing identifies genetic variants associated with co-trimoxazole hypersensitivity in Asians","volume":"147","author":"Wang","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.therap.2023.09.011_bib1600","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.annder.2019.01.010","article-title":"Hypersensibilit\u00e9 retard\u00e9e aux traitements antituberculeux. Proposition d\u2019une conduite \u00e0 tenir pratique devant un exanth\u00e8me\u00a0: quand arr\u00eater, quelles explorations allergologiques et comment r\u00e9introduire le traitement","volume":"146","author":"Ingen-Housz-Oro","year":"2019","journal-title":"Ann Dermatol Venerol"},{"key":"10.1016\/j.therap.2023.09.011_bib1605","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1159\/000112926","article-title":"Minocycline-induced DRESS: evidence for accumulation of the culprit drug","volume":"216","author":"Maubec","year":"2008","journal-title":"Dermatology"},{"key":"10.1016\/j.therap.2023.09.011_bib1610","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1001\/jamadermatol.2022.3541","article-title":"Risk factors for vancomycin drug reaction with eosinophilia and systemic symptoms syndrome","volume":"158","author":"Blumenthal","year":"2022","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.therap.2023.09.011_bib1615","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/S0140-6736(02)07873-X","article-title":"Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir","volume":"359","author":"Mallal","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.therap.2023.09.011_bib1620","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1056\/NEJMoa0706135","article-title":"HLA-B*5701 screening for hypersensitivity to abacavir","volume":"358","author":"Mallal","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.therap.2023.09.011_bib1625","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1097\/FPC.0b013e328330a3b8","article-title":"Strong association between HLA-B*5801 and allopurinol-induced Stevens\u2013Johnson syndrome and toxic epidermal necrolysis in a Thai population","volume":"19","author":"Tassaneeyakul","year":"2009","journal-title":"Pharmacogenet Genomics"},{"key":"10.1016\/j.therap.2023.09.011_bib1630","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1056\/NEJMoa1213096","article-title":"HLA-B*13:01 and the dapsone hypersensitivity syndrome","volume":"369","author":"Zhang","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.therap.2023.09.011_bib1635","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.jaci.2019.01.045","article-title":"HLA-A*32:01 is strongly associated with vancomycin-induced drug reaction with eosinophilia and systemic symptoms","volume":"144","author":"Konvinse","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.therap.2023.09.011_bib1640","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1038\/nature11147","article-title":"Immune self-reactivity triggered by drug-modified HLA-peptide repertoire","volume":"486","author":"Illing","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.therap.2023.09.011_bib1645","doi-asserted-by":"crossref","first-page":"9959","DOI":"10.1073\/pnas.1207934109","article-title":"Drug hypersensitivity caused by alteration of the MHC-presented self-peptide repertoire","volume":"109","author":"Ostrov","year":"2012","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/j.therap.2023.09.011_bib1650","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1016\/j.jid.2018.10.048","article-title":"Increased type 2 innate lymphoid cells in patients with drug reaction with eosinophilia and systemic symptoms syndrome","volume":"139","author":"Tsai","year":"2019","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.therap.2023.09.011_bib1655","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1016\/j.jaci.2008.04.005","article-title":"A novel IL-1 family cytokine, IL-33, potently activates human eosinophils","volume":"121","author":"Cherry","year":"2008","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.therap.2023.09.011_bib1660","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1038\/nature12526","article-title":"Type 2 innate lymphoid cells control eosinophil homeostasis","volume":"502","author":"Nussbaum","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.therap.2023.09.011_bib1665","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.jaip.2021.10.042","article-title":"Serum soluble OX40 as a diagnostic and prognostic biomarker for drug-induced hypersensitivity syndrome\/drug reaction with eosinophilia and systemic symptoms","volume":"10","author":"Mitsui","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.therap.2023.09.011_bib1670","doi-asserted-by":"crossref","first-page":"4441","DOI":"10.1182\/blood-2011-12-396101","article-title":"IL-5 promotes induction of antigen-specific CD4+CD25+ T regulatory cells that suppress autoimmunity","volume":"119","author":"Tran","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.therap.2023.09.011_bib1675","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1038\/nature13577","article-title":"The alarmin IL-33 promotes regulatory T-cell function in the intestine","volume":"513","author":"Schiering","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.therap.2023.09.011_bib1680","doi-asserted-by":"crossref","first-page":"9913","DOI":"10.1038\/srep09913","article-title":"Association of CD8+ T lymphocyte repertoire spreading with the severity of DRESS syndrome","volume":"5","author":"Niu","year":"2015","journal-title":"Sci Rep"},{"key":"10.1016\/j.therap.2023.09.011_bib1685","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2332\/allergolint.55.1","article-title":"Drug-induced hypersensitivity syndrome (DIHS): A reaction induced by a complex interplay among herpesviruses and antiviral and antidrug immune responses","volume":"55","author":"Shiohara","year":"2006","journal-title":"Allergol Int"},{"key":"10.1016\/j.therap.2023.09.011_bib1690","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.jaad.2012.08.009","article-title":"Long-term sequelae of drug reaction with eosinophilia and systemic symptoms: A retrospective cohort study from Taiwan","volume":"68","author":"Chen","year":"2013","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.therap.2023.09.011_bib1695","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1001\/archdermatol.2008.521","article-title":"Minocycline-induced drug hypersensitivity syndrome followed by multiple autoimmune sequelae","volume":"145","author":"Brown","year":"2009","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.therap.2023.09.011_bib1700","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1001\/jamadermatol.2020.0048","article-title":"Evaluation of cyclosporine for the treatment of DRESS syndrome","volume":"156","author":"Nguyen","year":"2020","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.therap.2023.09.011_bib1705","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1684\/ejd.2021.4103","article-title":"Immunosuppressants as steroid-sparing agents for chronic DRESS: four cases","volume":"31","author":"Ingen-Housz-Oro","year":"2021","journal-title":"Eur J Dermatol"},{"key":"10.1016\/j.therap.2023.09.011_bib1710","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.jdcr.2022.12.021","article-title":"Successful management with ganciclovir of drug reaction with eosinophilia and systemic symptoms secondary to antituberculous drugs associated to human herpesvirus-6 reactivation","volume":"34","author":"Corona-Rodarte","year":"2023","journal-title":"JAAD Case Rep"},{"key":"10.1016\/j.therap.2023.09.011_bib1715","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1016\/j.jaad.2018.08.052","article-title":"Drug-induced hypersensitivity syndrome\/drug reaction with eosinophilia and systemic symptoms severity score: A useful tool for assessing disease severity and predicting fatal cytomegalovirus disease","volume":"80","author":"Mizukawa","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.therap.2023.09.011_bib1720","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1007\/s40629-022-00224-7","article-title":"Treatment with IL5-\/IL-5 receptor antagonists in drug reaction with eosinophilia and systemic symptoms (DRESS)","volume":"32","author":"Gschwend","year":"2022","journal-title":"Allergo J Int"},{"key":"10.1016\/j.therap.2023.09.011_bib1725","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.jaip.2020.09.039","article-title":"Benralizumab for severe DRESS in two COVID-19 patients","volume":"9","author":"Schmid-Grendelmeier","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.therap.2023.09.011_bib1730","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1016\/j.jaip.2017.10.020","article-title":"Drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome successfully treated with mepolizumab","volume":"6","author":"Ange","year":"2018","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.therap.2023.09.011_bib1735","doi-asserted-by":"crossref","first-page":"e242240","DOI":"10.1136\/bcr-2021-242240","article-title":"Successful mepolizumab treatment for DRESS-induced refractory eosinophilic myocarditis and concurrent thyroiditis","volume":"14","author":"Truong","year":"2021","journal-title":"BMJ Case Rep"},{"key":"10.1016\/j.therap.2023.09.011_bib1740","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1093\/rheumatology\/keab662","article-title":"IgA vasculitis in patients with inflammatory bowel disease: new insights into the role of TNF-\u03b1 blockers","volume":"61","author":"Rasmussen","year":"2022","journal-title":"Rheumatology"},{"key":"10.1016\/j.therap.2023.09.011_bib1745","doi-asserted-by":"crossref","first-page":"102707","DOI":"10.1016\/j.autrev.2020.102707","article-title":"Drug-induced IgA vasculitis in children and adults: Revisiting drug causality using a dual pharmacovigilance-based approach","volume":"20","author":"Rasmussen","year":"2021","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.therap.2023.09.011_bib1750","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2018-227161","article-title":"Hydralazine-associated antineutrophil cytoplasmic antibody vasculitis with pulmonary\u2013renal syndrome","author":"Aeddula","year":"2018","journal-title":"BMJ Case Rep"},{"key":"10.1016\/j.therap.2023.09.011_bib1755","article-title":"Characteristics and outcome of ANCA-associated vasculitides induced by anti-thyroid drugs: a multicentre retrospective case-control study","author":"Culerrier","year":"2023","journal-title":"Rheumatology"},{"key":"10.1016\/j.therap.2023.09.011_bib1760","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1016\/S1470-2045(18)30608-9","article-title":"Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study","volume":"19","author":"Salem","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.therap.2023.09.011_bib1765","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1007\/s40264-019-00806-5","article-title":"Drug-induced photosensitivity\u2014an update: culprit drugs, prevention and management","volume":"42","author":"Blakely","year":"2019","journal-title":"Drug Saf"},{"key":"10.1016\/j.therap.2023.09.011_bib1770","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1111\/exd.12119","article-title":"Vemurafenib: an unusual UVA-induced photosensitivity","volume":"22","author":"Gelot","year":"2013","journal-title":"Exp Dermatol"},{"key":"10.1016\/j.therap.2023.09.011_bib1775","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.jaad.2009.09.033","article-title":"Chronic phototoxicity and aggressive squamous cell carcinoma of the skin in children and adults during treatment with voriconazole","volume":"62","author":"Cowen","year":"2010","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.therap.2023.09.011_bib1780","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1034\/j.1600-0536.2003.00066.x","article-title":"Spectrum of cross-photosensitization in 18 consecutive patients with contact photoallergy to ketoprofen: associated photoallergies to non-benzophenone-containing molecules: cross-photosensitization induced by ketoprofen","volume":"48","author":"Durbize","year":"2003","journal-title":"Contact Dermatitis"},{"key":"10.1016\/j.therap.2023.09.011_bib1785","doi-asserted-by":"crossref","first-page":"adv00224","DOI":"10.2340\/00015555-3457","article-title":"A Systematic review of drug-induced pemphigoid","volume":"100","author":"Verheyden","year":"2020","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.therap.2023.09.011_bib1790","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1111\/bjd.12488","article-title":"Linear IgA bullous dermatosis: comparison between the drug-induced and spontaneous forms","volume":"169","author":"Chanal","year":"2013","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.therap.2023.09.011_bib1795","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1111\/bcp.13827","article-title":"Drug-induced linear immunoglobulin A bullous dermatosis: A French retrospective pharmacovigilance study of 69 cases","volume":"85","author":"Garel","year":"2019","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.therap.2023.09.011_bib1800","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/S0738-081X(98)00010-8","article-title":"Drug-induced pemphigus","volume":"16","author":"Brenner","year":"1998","journal-title":"Clin Dermatol"},{"key":"10.1016\/j.therap.2023.09.011_bib1805","doi-asserted-by":"crossref","first-page":"107299","DOI":"10.1016\/j.intimp.2020.107299","article-title":"Drug-induced pemphigus: A systematic review of 170 patients","volume":"92","author":"Ghaedi","year":"2021","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.therap.2023.09.011_bib1810","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.annder.2021.02.006","article-title":"Cutaneous drug-induced lupus erythematosus: Clinical and immunological characteristics and update on new associated drugs","volume":"148","author":"Bataille","year":"2021","journal-title":"Ann Dermatol Venereol"},{"key":"10.1016\/j.therap.2023.09.011_bib1815","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1196\/annals.1422.019","article-title":"Drug-induced lupus","volume":"1108","author":"Borchers","year":"2007","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.therap.2023.09.011_bib1820","first-page":"465","article-title":"A systematic review of drug-induced subacute cutaneous lupus erythematosus: Systematic review of drug-induced SCLE","volume":"164","author":"Lowe","year":"2011","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.therap.2023.09.011_bib1825","doi-asserted-by":"crossref","first-page":"102705","DOI":"10.1016\/j.autrev.2020.102705","article-title":"Characterization of drug-induced cutaneous lupus: Analysis of 1994 cases using the WHO pharmacovigilance database","volume":"20","author":"Kawka","year":"2021","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.therap.2023.09.011_bib1830","doi-asserted-by":"crossref","first-page":"233","DOI":"10.2165\/11588900-000000000-00000","article-title":"Drug-induced acneiform eruption","volume":"12","author":"Du-Thanh","year":"2011","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.therap.2023.09.011_bib1835","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.1111\/jocd.15704","article-title":"Acneiform eruption induced by molecularly targeted agents in antineoplastic therapy: A review","volume":"22","author":"Yuan","year":"2023","journal-title":"J Cosmet Dermatol"},{"key":"10.1016\/j.therap.2023.09.011_bib1840","doi-asserted-by":"crossref","first-page":"adv11657","DOI":"10.2340\/actadv.v103.11657","article-title":"Acneiform Lesions but not acne after treatment with janus kinase inhibitors: diagnosis and management of janus kinase-acne","volume":"103","author":"Ballanger","year":"2023","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.therap.2023.09.011_bib1845","doi-asserted-by":"crossref","first-page":"253","DOI":"10.2165\/00128071-200102040-00006","article-title":"Drug-induced skin pigmentation: epidemiology, diagnosis and treatment","volume":"2","author":"Dereure","year":"2001","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.therap.2023.09.011_bib1850","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1111\/fcp.12558","article-title":"Drug-induced vitiligo: a case\/non-case study in Vigibase\u00ae, the WHO pharmacovigilance database","volume":"34","author":"Anthony","year":"2020","journal-title":"Fundam Clin Pharmacol"},{"key":"10.1016\/j.therap.2023.09.011_bib1855","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/S0190-9622(99)70488-3","article-title":"Mucocutaneous reactions to chemotherapy","volume":"40","author":"Susser","year":"1999","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.therap.2023.09.011_bib1860","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.jaad.2008.01.001","article-title":"Chemotherapeutic agents and the skin: An update","volume":"58","author":"Heidary","year":"2008","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.therap.2023.09.011_bib1865","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.revmed.2009.02.001","article-title":"Effets cutan\u00e9s des nouvelles mol\u00e9cules utilis\u00e9es en canc\u00e9rologie","volume":"30","author":"Mateus","year":"2009","journal-title":"Rev Med Interne"},{"key":"10.1016\/j.therap.2023.09.011_bib1870","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.jaad.2008.05.018","article-title":"Toxic erythema of chemotherapy: A useful clinical term","volume":"59","author":"Bolognia","year":"2008","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.therap.2023.09.011_bib1875","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1097\/00000441-200105000-00005","article-title":"Cutaneous reactions to chemotherapeutic agents","volume":"321","author":"Koppel","year":"2001","journal-title":"Am J Med Sci"},{"key":"10.1016\/j.therap.2023.09.011_bib1880","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.ejca.2022.02.019","article-title":"Life-threatening skin reaction with enfortumab vedotin: six cases","volume":"167","author":"Guerrois","year":"2022","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.therap.2023.09.011_bib1885","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/S0151-9638(08)70093-0","article-title":"Effets secondaires cutan\u00e9s des nouvelles mol\u00e9cules anticanc\u00e9reuses\u00a0: focus sur les mol\u00e9cules ciblant les r\u00e9cepteurs tyrosine kinase et le r\u00e9cepteur \u00e0 l\u2019EGF","volume":"Spec. No. 1","author":"Deslandres","year":"2008","journal-title":"Ann Dermatol Venereol"},{"key":"10.1016\/j.therap.2023.09.011_bib1890","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.annonc.2020.11.005","article-title":"Prevention and management of dermatological toxicities related to anticancer agents: ESMO Clinical Practice Guidelines","volume":"32","author":"Lacouture","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.therap.2023.09.011_bib1895","doi-asserted-by":"crossref","first-page":"5078","DOI":"10.1002\/cncr.27505","article-title":"Clinical and histopathologic characteristics of rash in cancer patients treated with mammalian target of rapamycin inhibitors: mTOR inhibitor-related rash","volume":"118","author":"Balagula","year":"2012","journal-title":"Cancer"},{"key":"10.1016\/j.therap.2023.09.011_bib1900","doi-asserted-by":"crossref","first-page":"5235","DOI":"10.1200\/JCO.2005.00.6916","article-title":"Cutaneous adverse effects with HER1\/EGFR-targeted agents: is there a silver lining?","volume":"23","author":"Per\u00e9z-Soler","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.therap.2023.09.011_bib1905","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S1470-2045(05)70243-6","article-title":"Cutaneous side-effects of kinase inhibitors and blocking antibodies","volume":"6","author":"Robert","year":"2005","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.therap.2023.09.011_bib1910","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1093\/jnci\/djp439","article-title":"Dermatologic infections in cancer patients treated with epidermal growth factor receptor inhibitor therapy","volume":"102","author":"Eilers","year":"2010","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.therap.2023.09.011_bib1915","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.annder.2012.12.012","article-title":"Anomalies pigmentaires induites par les traitements anticanc\u00e9reux. Premi\u00e8re partie\u00a0: les chimioth\u00e9rapies","volume":"140","author":"Sibaud","year":"2013","journal-title":"Ann Dermatol Venereol"},{"key":"10.1016\/j.therap.2023.09.011_bib1920","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/j.det.2019.05.013","article-title":"Cutaneous adverse reactions of anticancer agents","volume":"37","author":"Kaul","year":"2019","journal-title":"Dermatol Clin"},{"key":"10.1016\/j.therap.2023.09.011_bib1925","doi-asserted-by":"crossref","first-page":"68","DOI":"10.2165\/11537080-000000000-00000","article-title":"Flagellate dermatitis as a bleomycin-specific adverse effect of cytostatic therapy: a clinical-histopathologic correlation","volume":"12","author":"Ziemer","year":"2011","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.therap.2023.09.011_bib1930","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1001\/archderm.1993.01680260116021","article-title":"Recall of cutaneous toxicity from fluorouracil","volume":"129","author":"Prussick","year":"1993","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.therap.2023.09.011_bib1935","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.jaad.2005.01.127","article-title":"Serpentine supravenous streaks induced by 5-fluorouracil","volume":"53","author":"Jain","year":"2005","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.therap.2023.09.011_bib1940","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1159\/000246423","article-title":"Chemotherapy-associated supravenous hyperpigmentation","volume":"192","author":"Baselga","year":"1996","journal-title":"Dermatology"},{"key":"10.1016\/j.therap.2023.09.011_bib1945","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1159\/000439047","article-title":"Chemotherapy-related reticulate hyperpigmentation: a case series and review of the literature","volume":"231","author":"Masson Regnault","year":"2015","journal-title":"Dermatology"},{"key":"10.1016\/j.therap.2023.09.011_bib1950","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1097\/CMR.0b013e328322fc20","article-title":"Immunosuppression and melanocyte proliferation","volume":"19","author":"Zattra","year":"2009","journal-title":"Melanoma Res"},{"key":"10.1016\/j.therap.2023.09.011_bib1955","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1080\/17425255.2017.1247155","article-title":"Drug-induced eruptive melanocytic nevi","volume":"13","author":"Vena","year":"2017","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1016\/j.therap.2023.09.011_bib1960","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1016\/j.jaad.2017.06.044","article-title":"Pigmentary changes in patients treated with targeted anticancer agents: A systematic review and meta-analysis","volume":"77","author":"Dai","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.therap.2023.09.011_bib1965","first-page":"844","article-title":"Vitiligo-like Hypopigmentation with poliosis following treatment of superficial basal cell carcinoma with imiquimod","volume":"34","author":"Jacob","year":"2008","journal-title":"Dermatol Surg"},{"key":"10.1016\/j.therap.2023.09.011_bib1970","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1007\/s40257-017-0336-3","article-title":"Dermatologic reactions to immune checkpoint inhibitors: skin toxicities and immunotherapy","volume":"19","author":"Sibaud","year":"2018","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.therap.2023.09.011_bib1975","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.det.2007.08.006","article-title":"Cutaneous reactions to chemotherapy: commonly seen, less described, little understood","volume":"26","author":"Sanborn","year":"2008","journal-title":"Dermatol Clin"},{"key":"10.1016\/j.therap.2023.09.011_bib1980","doi-asserted-by":"crossref","first-page":"418","DOI":"10.5114\/ada.2017.71106","article-title":"The incidence and management of cutaneous adverse events of the epidermal growth factor receptor inhibitors","volume":"5","author":"Owczarek","year":"2017","journal-title":"Adv Dermatol Allergol"},{"key":"10.1016\/j.therap.2023.09.011_bib1985","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1001\/jamadermatol.2016.2226","article-title":"Clinical and histologic features of lichenoid mucocutaneous eruptions due to anti\u2013programmed cell death 1 and anti\u2013programmed cell death ligand 1 immunotherapy","volume":"152","author":"Shi","year":"2016","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.therap.2023.09.011_bib1990","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1172\/JCI16432","article-title":"CD28-dependent Rac1 activation is the molecular target of azathioprine in primary human CD4+ T lymphocytes","volume":"111","author":"Tiede","year":"2003","journal-title":"J Clin Invest"},{"key":"10.1016\/j.therap.2023.09.011_bib1995","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1186\/s13256-022-03621-2","article-title":"Delayed pharyngocutaneous fistula caused by molecular targeted therapy: a case report","volume":"16","author":"Matsuo","year":"2022","journal-title":"J Med Case Reports"},{"key":"10.1016\/j.therap.2023.09.011_bib2000","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1111\/iwj.13139","article-title":"Impaired wound healing secondary to bevacizumab","volume":"16","author":"Ahn","year":"2019","journal-title":"Int Wound J"},{"key":"10.1016\/j.therap.2023.09.011_bib2005","first-page":"10","article-title":"Anti-angiog\u00e9niques, cicatrisation et chirurgie - Aspects pratiques","volume":"8","author":"Dansin","year":"2013","journal-title":"E-VEGF-IMMUNO-Actu"},{"key":"10.1016\/j.therap.2023.09.011_bib2010","doi-asserted-by":"crossref","first-page":"e50","DOI":"10.1016\/S1470-2045(12)70553-3","article-title":"Pathobiology of chemotherapy-induced hair loss","volume":"14","author":"Paus","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.therap.2023.09.011_bib2015","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1634\/theoncologist.2013-0193","article-title":"Alopecia with endocrine therapies in patients with cancer","volume":"18","author":"Saggar","year":"2013","journal-title":"Oncologist"},{"key":"10.1016\/j.therap.2023.09.011_bib2020","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1038\/nrc1970","article-title":"Mechanisms of cutaneous toxicities to EGFR inhibitors","volume":"6","author":"Lacouture","year":"2006","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.therap.2023.09.011_bib2025","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s40257-018-0384-3","article-title":"Toxic side effects of targeted therapies and immunotherapies affecting the skin, oral mucosa, hair, and nails","volume":"19","author":"Lacouture","year":"2018","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.therap.2023.09.011_bib2030","first-page":"77","article-title":"Ongles et m\u00e9dicaments","volume":"2011","author":"Lebrun-Vignes","year":"2011","journal-title":"Rev Francoph Lab"},{"key":"10.1016\/j.therap.2023.09.011_bib2035","doi-asserted-by":"crossref","first-page":"e181","DOI":"10.1016\/S1470-2045(14)71133-7","article-title":"Nail toxicities induced by systemic anticancer treatments","volume":"16","author":"Robert","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.therap.2023.09.011_bib2040","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.jdcr.2021.02.016","article-title":"Anti-programmed cell death protein 1-induced lichenoid changes of the nail unit: histopathologic description","volume":"10","author":"Van Damme","year":"2021","journal-title":"JAAD Case Rep"},{"key":"10.1016\/j.therap.2023.09.011_bib2045","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1034\/j.1600-0536.2001.450601.x","article-title":"Guidelines for performing skin tests withdrugs in the investigation of cutaneous adverse drug reactions: Proposed by the Working party of the ESCD for the study of skin testing in investigating cutaneous adverse drug reactions","volume":"45","author":"Barbaud","year":"2001","journal-title":"Contact Dermatitis"},{"key":"10.1016\/j.therap.2023.09.011_bib2050","doi-asserted-by":"crossref","first-page":"156","DOI":"10.3389\/fmed.2020.00156","article-title":"Intradermal tests with drugs: an approach to standardization","volume":"7","author":"Barbaud","year":"2020","journal-title":"Front Med"},{"key":"10.1016\/j.therap.2023.09.011_bib2055","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.annder.2018.01.005","article-title":"Investigations allergologiques dans les \u00e9ryth\u00e8mes pigment\u00e9s fixes. M\u00e9thode recommand\u00e9e par le groupe FISARD de la SFD","volume":"145","author":"Barbaud","year":"2018","journal-title":"Ann Dermatol Venereol"},{"key":"10.1016\/j.therap.2023.09.011_bib2060","doi-asserted-by":"crossref","first-page":"3252","DOI":"10.1016\/j.jaip.2022.07.008","article-title":"Skin testing and drug provocation tests in epidermal necrolysis: a French experience","volume":"10","author":"Roux","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.therap.2023.09.011_bib2065","first-page":"427","article-title":"Organisation et int\u00e9r\u00eat de la pharmacovigilance","volume":"2","author":"Lebrun-Vignes","year":"2022","journal-title":"Ann Dermatol Venereol - FMC"},{"key":"10.1016\/j.therap.2023.09.011_bib2070","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.annder.2022.08.011","article-title":"Bidisciplinary dermatology-pharmacovigilance consultations: Results of a two-year study","volume":"150","author":"Sanchez-Pena","year":"2023","journal-title":"Ann Dermatol Venereol"}],"container-title":["Therapies"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595723001750?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595723001750?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T04:51:49Z","timestamp":1730436709000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0040595723001750"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":215,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["S0040595723001750"],"URL":"https:\/\/doi.org\/10.1016\/j.therap.2023.09.011","relation":{},"ISSN":["0040-5957"],"issn-type":[{"value":"0040-5957","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cutaneous adverse drug reactions","name":"articletitle","label":"Article Title"},{"value":"Therapies","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.therap.2023.09.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Soci\u00e9t\u00e9 fran\u00e7aise de pharmacologie et de th\u00e9rapeutique. Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}